Interferon-alpha-2a and zinc combination therapy in cildren with chronic hepatitis B infection.
No Thumbnail Available
Date
2011-12
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Zinc has been reported to enhance the response to interferon (IFN) or PEG-IFN plus
ribavirin therapy, improve liver function, and ameliorate hematologic side effects in patients
with chronic hepatitis C. However, the role of zinc supplementation during IFN therapy in
chronic hepatitis B infection (CHB) remains unclear. We therefore aimed to report the results of
zinc and IFN-alpha-2a therapy in children with CHB. Twenty-two naive, HBeAg-positive
children (mean age 10.4±4.4 years) received IFN-!2a (9 MU/m2 sc) for 6 months plus peroral
zinc (7.5 mg/day for <10 years and 10 mg/day for >10 years) for 12 months. Serum zinc,
alanine aminotransferase (ALT), complete blood count, hepatitis B virus DNA (HBV DNA),
and serological markers were measured. Histological (HR) and sustained response (SR) were
evaluated at 6 months after completion of therapy. Normalization of ALT, HBeAg
seroconversion, and HBV DNA<10,000 copies/ml were considered as SR. HR was defined
as decrease in Knodell histological activity index (HAI) score by at least 2 points
compared to baseline. End of therapy ALT level and log HBV DNA were significantly
lower than pretherapy levels (p=0.001 and p=0.001, respectively), while zinc level was
not different. Portal inflammation score significantly decreased after therapy (p=0.043),
however, total HAI and other HAI components were not different. SR and HR were 25%
and 52.9%. In conclusion as a first study investigating the effect of zinc and IFN
combination therapy in children with CHB, SR and HR rates were not better than
previously reported monotherapy or combination therapies.
Description
Keywords
Children . Chronic Hepatitis B infection . Interferon . Zin